The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | Bone marrow versus mobilized peripheral blood grafts for haploidentical transplant in secondary AML
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, comments on the findings of a study comparing bone marrow and mobilized peripheral blood grafts in haploidentical transplantation for secondary acute myeloid leukemia (AML). While there was no significant difference in outcomes between the two groups, chronic graft-versus-host disease (GvHD) incidence was higher in patients receiving peripheral blood grafts. Prof. Nagler notes that the graft-versus-leukemia (GVL) effect and relapse rates did not differ significantly between the two graft types, and that the choice between bone marrow and peripheral blood grafts largely depends on technical considerations. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Secondary AML is difficult to treat. The best, I mean, haploidentical may overcome some of the bad signals in secondary AML. And we know from the biology of transplantation that the graft versus leukemia effect, which is extremely important in transplant, is stronger with peripheral blood than in bone marrow. On the other hand, the graft versus host disease that is the main obstacle for successful transplant is stronger with peripheral blood...
Secondary AML is difficult to treat. The best, I mean, haploidentical may overcome some of the bad signals in secondary AML. And we know from the biology of transplantation that the graft versus leukemia effect, which is extremely important in transplant, is stronger with peripheral blood than in bone marrow. On the other hand, the graft versus host disease that is the main obstacle for successful transplant is stronger with peripheral blood. So, we ask whether bone marrow or peripheral blood is the preferable graft for secondary AML. These studies were done for de novo AML and other malignancies.
And here we found that there was no major difference between patients with secondary AML that received bone marrow graft or peripheral blood stem cells, beside some more chronic GVHD as expected in the patients with peripheral blood. But we failed to show that there is stronger graft versus leukemia effect or less relapse in patients with secondary AML that received haplo with peripheral blood than bone marrow.
So I mean, it depends on the starting of the haploidentical from the Baltimore was with bone marrow. Most of the world is giving now peripheral blood because of technical, it’s hard to go to the operating room, it’s much easier peripheral blood. Here we show that there is no major difference between the two in secondary AML.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
